143879-61-2

Upstream product

• 53078-85-6 2-bromo-5-methylaniline 
• 75927-49-0 pinacol vinylboronate 
• 108-44-1 1-amino-3-methylbenzene 

Downstream Products

• 1161929-08-3 C₁₈H₁₈BrN 
• 1161929-09-4 C₁₅H₂₁N 
• 1346130-61-7 (S)-5-methyl-N-(1-phenylallyl)-2-vinylaniline 
• 4748-81-6 2-ethyl-5-methylaniline 

Relevant academic research and scientific papers

Electrochemical-mediated fixation of CO2: three-component synthesis of carbamate compounds from CO2, amines andN-alkenylsulfonamides

An electrocatalyzed three-component cascade reaction of CO2, amines, andN-alkenylsulfonamides is developed, providing an environmentally friendly and efficient method of synthesizing a series of new carbamate compounds. This reaction meets the needs of green chemistry and promotes the participation of carbon dioxide in the three-component reaction by electro-oxidation. Pharmacological activity studies further prove that carbamate compounds have better activity than diamination by-products.

Direct Synthesis of Structurally Divergent Indole Alkaloids from Simple Chemicals

A direct and structurally divergent synthesis of indole alkaloids from very simple 2-vinylanilines, alkynes and TBN via a novel substrate fragmentation/cycloaddition strategy has been developed, which provides an efficient noble-metal-free approach to access a library of highly valuable indole derivatives of tryptamines and tryptamine-related oximes, lactams, and lactones, as well as β-carbolines, spiroindolines, and hexa-hydropyrrolo[2,3-b]indoles.

THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER

A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.